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Summary A novel resistant variant of murine P388 leukaemia, P388/SPR, was identified by de novo resistance to doxorubicin (DOX) in vivo.
This mutant displayed a similar level of cross-resistance to etoposide (VP-16) and other topoisomerase 11 (topo 11) inhibitors. Further analysis
of the phenotype revealed a broad cross-resistance to vinca alkaloids, alkylating agents, antimetabolites, aphidicolin and UV light. Low-level
expression of mdrl and P-glycoprotein (P-gp), as well as a modest impairment of cellular drug accumulation and partial reversion of
resistance to DOX and VP-16 by cyclosporine, confirmed a moderate role of P-gp in conferring drug resistance in P388/SPR cells. Consistent
changes in neither topo 11 expression or activity nor glutathione metabolism could be detected. Induction of apoptosis was significantly
reduced in P388/SPR cells, as indicated by minimal DNA fragmentation. Analysis of oncogenes regulating apoptotic cell death revealed a
marked decrease of bcl-2 in combination with a moderate reduction of baxprotein, but a striking overexpression of the long form of the bcl-X
protein. Transfection of human bcl-X-L into P388 cells conferred drug resistance similar to that of P388/SPR cells. The data suggest that
overexpression of bcl-X-L results in an unusual phenotype with broad cross-resistance to non-MDR-related cytotoxins in vitro, and provide an
interesting example of spontaneous overexpression of another member of the bcl-2gene family in cancer.
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The mechanisms ofaction ofdoxorubicin (DOX) are complex and
include free radical formation (Bachur et al, 1978), membrane
effects (Tritton et al, 1978), DNA intercalation and disruption of
topoisomerase II (topo II) action (Tewey et al, 1984), as well as
induction of apoptosis (Ling et al, 1993). P-glycoprotein (P-gp)
and changes in topo II expression or activity are well-known
mechanisms of resistance to DOX (Kartner et al, 1985; Deffie et
al, 1989; Ganapathi et al, 1989; Baas et al, 1990) (for review see
Endicott and Ling, 1989; Hochhauser and Harris, 1993). Other
alternative mechanisms include increased glutathione (GSH)
levels (Kramer et al, 1988; Rabier et al, 1991) or glutathione-
S-transferase (GST) activity (Nakagawa et al, 1990) and inhibition
of programmed cell death by overexpression of bcl-2 or loss of
p53 (Lowe et al, 1993; Miyashita and Reed, 1993). Resistance to
DOX may be multifactorial, with several of these mechanisms
involved (Baas et al, 1990; Rabier et al, 1991; Datta et al, 1995).
The aforementioned mechanisms have predominantly been
studied in cell lines purposely rendered resistant by treatment with
increasing drug concentrations in vitro. We report herein a novel
resistance phenotype of a variant of the murine P388 leukaemia,
which was observed to be resistant to DOX after in vivo passaging
without drug selection. Analysis ofthese drug-resistant leukaemia
cells revealed marked overexpression of bcl-X-L, thus providing
an example of spontaneously occurring deregulated bcl-X-L








The drugs used in this study and their sources are as follows: etopo-
side (VP-16) and cisplatin (Bristol Laboratories, Syracuse, NY,
USA), doxorubicin (DOX; Adria Laboratories, Columbus, OH,
USA), vinblastine (Eli Lilly, Indianapolis, IN, USA), cytarabine
(Ara C; Upjohn, Kalamazoo, MI, USA), mitoxantrone (Lederle
Laboratories, Pearl River, NY, USA), 4-hydroperoxycyclophos-
phamide (4-OH-cyclophosphamide; Nova Pharmaceuticals,
Baltimore, MD, USA) and cyclosporine (Basle, Switzerland).
Camptothecin and amsacrine (generously provided by Dr Y
Pommier, National Cancer Institute, Bethesda, MD, USA) were
first dissolved in dimethyl sulphoxide (DMSO); final solvent
concentration did not exceed 0.1%. [3H]vinblastine was obtained
from Moravek Biochemicals (Brea, CA, USA). [methyl-3H]thymi-
dine, [R-32P]dCTP and ['25I]protein A were purchased from
Amersham (Arlington Heights, IL, USA), ['251]goat anti-mouse
IgG antibody from ICN (Irvine, CA, USA). If not indicated, other
chemicals were purchased from Sigma (St Louis, MO, USA) and
tissue culture reagents from Gibco (Grand Island, NY, USA).
Cell culture
Parental murine P388 cells as well as the spontaneously resistant
variant P388/SPR were kindly provided by Dr David Streeter
(SRI International, Menlo Park, CA, USA). The P388/SPR variant
arose after continuous growth with multiple passages of drug-
sensitive P388 cells in vivo; the cells were identified by their spon-
taneous resistance to DOX in vivo (Dr David Streeter, personal
communication). Aliquots of P388/SPR cells that had not been
exposed to drug before were used for the in vitro characterization.
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These cells were not cloned. The P-gp-positive 'classical' MDR
subline P388/ADR was obtained from Dr J G Mayo (National
Cancer Institute, Frederick, MD, USA). The identical origin of
these lines was confirmed by karyotype analysis, H2-phenotyping
and restriction fragment length polymorphism (RFLP) of the
highly polymorphic D-loop region of mitochondrial DNA (data
not shown). Cells were maintained in vitro as standard suspension
cultures as described (Kuhl et al, 1993).
For transfection studies, parental P388 cells were electroporated
with the BCMGS-Neo plasmid with or without human bcl-X
cDNA (Kuhl et al, manuscript in preparation). Transfectants were
selected for neomycin resistance and stable clones were obtained
by limited dilution. A clone overexpressing bcl-X-L protein by at
least five fold was used for cytotoxicity experiments.
MTT cytotoxicity assays
Drug sensitivity was compared employing the MUT cytotoxicity
assay after a 48-h (approximately four generation times) drug
incubation period as previously described (Kuhl et al, 1993). IC50
values were calculated from semilogarithmic dose-response
curves by linear interpolation.
Accumulation studies
Uptake of radioactivity by P388/SPR cells in comparison with
parental P388 cells incubated in 100 nM [3H]vinblastine at 37°C
was studied according to the method previously described (Lau
et al, 1991).
Western blot analysis
Standard denaturing sodium dodecyl sulphate polyacrylamide gel
electrophoresis (SDS-PAGE) and Western blotting for P-gp and
GSTs were done as described (Lau et al, 1991) using the P-
gp-detecting antibody C219 (Kartner et al, 1985) or specific rabbit
GST antibodies raised against the human 7i class GST (X, YfYf
subunits) as well as human a class GST (B,B1, YaYa subunit)
respectively. Samples for detection of topo II were prepared and
Western blots carried out as described before (Drake et al, 1987).
Antibodies against both isoforms of human topo II were gener-
ously provided by Dr F Drake (Smith Kline, King of Prussia, PA,
USA). Polyclonal rabbit antibodies against murine bcl-2, bax and
bcl-X were raised and immunoblots performed as described
(Krajewski et al, 1994, 1996). Specific bands were quantitated
using the integrated image analysis system MicroComp from
Southern Micro Instruments (Atlanta, GA, USA).
Immunocytochemistry
Approximately 5 x 104 cells were applied to glass slides by cyto-
centrifugation, air dried and fixed in 4% acetone. The slides
were rinsed with phosphate-buffered saline (PBS) and incubated
with monoclonal antibodies against P-gp (C219; Centocor,
Malvern, PA, USA), wild-type and mutant p53 (PAb 421 and
PAb 240; Oncogene Science, Uniondale, NY, USA), c-myc (LA
070; Quality Biotech, Camden, NJ, USA) and the retinoblastoma
gene (RB-PMG3-245; PharMingen, San Diego, CA, USA).
Following incubation with a secondary biotin-conjugated goat
anti-mouse antibody (Jackson Immunoresearch Laboratories,
West Grove, PA, USA), slides were developed by a standard
streptavidin-horseradish peroxidase method (Jackson). Immuno-
cytochemistry for bcl-2 and bcl-X was done as described (Hanada
et al, 1993). Cells were counterstained with methyl blue or green.
For bcl-2 family proteins, either the antisera after peptide compe-
tition or preimmune rabbit sera served as appropriate controls. In
all other experiments, PBS instead of the primary antibody was
used as negative control. Varying dilutions of primary antibody
were compared, and slides were scored by three different investi-
gators as negative, one, two or three plus.
Polymerase chain reaction (PCR) studies
Gene expression of mdrl, topo IIa, topo II,B and bcl-2 was semi-
quantitatively determined similar to the method described by
Noonan et al (1988). cDNA was synthesized from total cellular
RNA using random hexadeoxynucleotide primers (Pharmacia,
Milwaukee, WI, USA). Primers used were derived from human
sequences as follows (numbers refer to GenBank positions): 5'
(3020-3037), 3' (3168-3187) for mdrl; 5' (1136-1163), 3'
(1649-1676) fortopo IIa; 5' (2079-2102), 3' (2359-2382) fortopo
IlI; 5' (104-124), 3' (456-476) for bcl-2; and 5' (1501-1520), 3'
(1827-1846) for 28S rRNA. Each primer set detected highly
homologous fragments of identical length to the corresponding
murine genes. Serial dilutions of cDNA were used as template to
assure amplification within a linear range and PCR was carried out
using standard conditions as described before (Brophy et al, 1994).
Quantitation was done by incorporation of [e-32P]dCTP and gene
expression was standardized on the basis of28S rRNA message as
an index of total cellular RNA content. Negative controls using
water instead of template were included in all experiments. The
ratio ofspecific gene expression (background subtracted) vs rRNA
message was calculated and arbitrarily set to 100 units for
P388/ADR (mdrl) or for P388 cells (topo Ia3p, bcl-2).
K-SDS precipitation assay for protein-DNA complexes
The in vitro formation ofcovalent topoisomerase-DNA complexes,
so-called cleavable complexes, was quantitated to assess topoiso-
merase activity. Cells in early log phase (2 x 105 cells per ml) were
prelabelled with [methyl-3H]thymidine at a final concentration of
0.5 ,uCi ml-' for 24 h. Harvested cells were washed and nuclei were
isolated as described (Ganapathi et al, 1989). Nuclei were treated
with various concentrations of VP-16 in the presence of ATP
(1 mM) or with camptothecin in the absence of ATP for 30 min
at 37°C respectively. Nuclei were then lysed and processed as
reported (Rowe et al, 1986). The percentage ofspecifically precipi-
tated DNA was calculated.
Glutathione and glutathione-dependent enzyme
measurements
Cells were harvested in mid-log phase (approximately 5 x l05 cells
per ml) and washed twice in PBS. For the analysis of GSH, cells
were extracted in 20 mm 5-sulphosalicylic acid and samples stored
at 4°C. GSH was later determined by high-performance liquid
chromatography (HPLC) using monobromobimane as described
(Minchinton, 1984). For GST activities, cells were sonicated,
centrifuged and the activity toward CDNB in the supematant was
assayed as described (Lau et al, 1991).
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Table 1 Resistance phenotype of P388/SPR and P388/ADR cells in comparison with parental P388 cells
P388 P388/SPR Resistance P388/ADR Resistance
Drugs ICO (nM) IC5. (nM) factora ICso (nM) factorb
Doxorubicin 23 (17-30)c 234 (91-604) 10 5125 (3327-7894) 227
Doxorubicin and 2.5 gM CsA 13 (6-20) 67 (58-76) 5 (2)d 53 (36-70) 4 (56)d
VP-16 85 (77-94) 1458 (1356-1626) 17 9527 (8978-10 110) 112
VP-16 and 2.5 IbM CsA 20 (14-28) 142 (59-343) 7 (2)d 124 (104-148) 6 (18)d
Amsacrine 8 (7-9) 53 (36-76) 7 338 (296-387) 42
Mitoxantrone 1.7 (1.1-2.5) 11 (8-14) 6 235(188-293) 141
Vinblastine 1.5 (1.3-1.8) 4.3 (3.8-4.8) 3 97(88-107) 64
Camptothecin 22 (20-25) 70 (48-104) 3 24 (20-28) 1
Cisplatin 583(456-745) 4767(3395-6695) 8 1868(1627-2146) 3
4-OH-Cyclophosphamide 960 (676-1362) 6124 (4250-8825) 6 924 (651-1311) 1
Cytarabine 41 (31-54) 83 (61-114) 2 26 (20-35) 0.6
Aphidicolin 246 (224-270) 893 (696-1087) 4 N D -
UV irradiation (254 nm) 11 (10-13)- 21 (16-27)e 1.8 13 (12-15)e 1.2
CsA, cyclosporine; ND, not determined. Resistance factor: x-fold increase of IC50 in comparison with P388 cells as determined by MTT assays (n=4-8) after 48-
h drug exposure (aall numbers P<0.05 compared with P388 cells; ball numbers P<0.05 compared with P388/SPR cells). cNumbers: means (95% confidence
limits). d Modulation factor = ratio of resistance factors with and without CsA.e Unit: J m-2.
Quantitation of apoptosis by enzyme-linked
immunosorbent assay (ELISA)
A 'cell death' ELISA (Boehringer Mannheim, Mannheim,
Germany) that measures cytoplasmic DNA-histone complexes
generated during apoptotic DNA fragmentation was employed to
quantitate induction of apoptosis. Cytoplasmic extracts of 2 x 103
cells were used and the ELISA performed according to the manu-
facturer's specifications. Time points and drug concentrations
were selected so that >70% of P388 cells were still vital as deter-
mined by trypan blue exclusion.
Statistical analysis
Significance levels of mRNA and protein quantitation were calcu-
lated using the Mann-Whitney U-test. Significance of all other
data was tested by a two-tailed Student's t-test.
RESULTS
Phenotypic characterization
The P388/SPR subline was phenotypically characterized by its
cross-resistance pattern to different cytotoxic drugs. The results of
MTT assays after a 48-h drug incubation period are summarized in
Table 1. P388/SPR cells displayed the highest degree ofresistance
to DOX and to VP-16. Both could be partially reversed (twofold)
by the addition of 2.5 tM cyclosporine. To a somewhat lesser
degree, cross-resistance was also observed for other topo II
inhibitors, such as amsacrine and mitoxantrone. The relative
low resistance levels of P388/SPR cells in comparison with the P-
gp-positive P388/ADR subline, especially the low degree ofcross-
resistance to vinblastine (threefold) and the partial sensitization
by cyclosporine (modulation factor of 2), suggested a limited role
of mdrl-mediated resistance in this variant. In contrast to the
P388/ADR variant, however, P388/SPR cells displayed significant
cross-resistance to cross-linking agents, such as cisplatin and 4-
OH-cyclophosphamide, to the topoisomerase I inhibitor camp-
tothecin, to the antimetabolite cytarabine, to aphidicolin, an
inhibitor ofDNA polymerase oc, as well as to UV light. There was
no significant difference in doubling time in vitro between P388
cells with 11.1 ± 0.5 h and P388/SPR cells with 10.9 ± 0.7 h.
Karyotypic analysis revealed a modification of marker chromo-
some M2 and the loss of M5 in P388/SPR cells, suggesting that
the P388/SPR cells arose by the expansion of an altered clone
(data not shown).
mdrl gene and P-gp expression
To determine the role of P-gp or other drug transport mechanisms,
accumulation studies were performed. P388/SPR cells were charac-
terized by a moderate impairment of cellular accumulation of
vinblastine leveling off at about 77% of parental P388 cells. In
contrast, drug accumulation was greatly reduced in P388/ADR
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Figure 1 Intracellular accumulation of [3H]vinblastine by P388 (0),
P388/SPR (-) and P388/ADR cells (A) in the presence of 100 nm
vinblastine. Each point represents the mean of three separate experiments
done in duplicate. Bars indicate + s.d.











Figure 2 Western blot analysis of P-glycoprotein (A) and topoisomerase 11
(B) content in P388 and P388/SPR cells. Immunoblots were carried out as
described (see Material and methods) with the amount of soluble protein per
track indicated. P-gp was identified by the monoclonal antibody C219; topo 11
by the polyclonal antibody 29, which detects both isoforms (a = 170 kDa; ,B =
180 kDa). P388/ADR cells were used as positive control for P-gp
obtained using VP-16 (data not shown). Low but significant
mRNA levels of the mdrl gene in P388/SPR cells could be
detected by reverse transcription-polymerase chain reaction
(RT-PCR). Compared with the MDR variant P388/ADR, for which
mdrl mRNA expression was readily apparent and set to 100 units,
P388/SPR cells contained a median value of 4.9 units of mdrl
mRNA vs 0.4 units for P388 cells (P<0.005). The latter number
was not significantly different from background levels. P-gp
protein expression was studied by Western blotting (Figure 2A) and
immunocytochemistry (Table 2). Again, levels in P388/SPR cells
were rather low when compared with P388/ADR cells, in which
protein levels were approximately 14-fold higher than in P388/SPR
cells. P-gp expression was not detectable in the parental cells.
Topo 11 expression and activity
Expression ofthe two topo II isoforms was measured by RT-PCR
and Western blotting. PCR studies did not reveal significant differ-
ences with a median value of92 units for topo IIx and 80 units for
topo II3 in P388/SPR cells (relative expression was set to 100 units
for P388 cells) respectively. Western blot analysis indicated
a decrease of topo IIcx (170-kDa isoform) by approximately 50%
and a doubling in topo II (180-kDa isoform) expression
compared with parental cells (Figure 2B). The K-SDS assay,
which measures the formation of cleavable complexes, was
employed to detect topo II activity. These experiments were
performed on isolated nuclei in the presence of 1 mm ATP to
exclude any differences in cellular drug accumulation. There was a
dose-dependent, VP-16-induced formation ofcleavable complexes











Figure 3 Western blot analysis of bcl-2and bax (A) as well as bcl-X(B)
content in P388 and P388/SPR cells. A total of 50 gg of soluble protein per
track were loaded. Respective proteins were identified by specific rabbit
antisera (see Material and methods). Both forms of the bcl-Xprotein were
detected by the antiserum as indicated by the positive control (lane 1, B)
Similar experiments using camptothecin in the absence of ATP
indicated no difference in the topoisomerase I activity ofP388 and
P388/SPR cells also.
GSH and expression of GSTs
The GSH content in P388/SPR cells was 3.3 ± 0.3 fmol per cell
(mean ± s.d.), which is about 50% greater than in P388 cells that
contained 2.2 ± 0.5 fmol per cell (P<0.05). In contrast, the
P388/SPR variant displayed with 68 ± 6 nmol min-' mg-' protein a
significant decrease in total GST activity compared with 111 ± 14
nmol min-m mg-' protein in P388 cells. Quantification of the
protein expression of GST-x and GST-ir subclasses implied that
the difference is caused by a corresponding decrease in GST-ir
protein levels of about 60% relative to the parental cells.
Expression of oncogenes regulating apoptotic cell
death and measurement of induction of apoptosis
We measured the protein expression of some tumour-suppressor
genes and oncogenes implicated in the regulation ofapoptosis and
cell growth. Western blot analysis of the expression of bcl-2 and
related proteins is shown in Figure 3. By the technique used, bcl-2
protein was not detectable in P388/SPR cells in contrast to easily
detectable levels in the parental cells (Figure 3A). This was in
agreement with a significant decrease of bcl-2 mRNA expression
Table 2 Protein expression of P-gp, bcl-2, bcl-X, mutant p53, c-myc and the retinoblastoma gene product in P388 vs P388/SPR and P388/ADR cells detected
by immunocytochemistry
P-gp bc1-2 bcl-X p53 c-myc Retinoblastoma
(mutant) gene product
P388 - ++ + ++ ++ ++
P388/SPR + - ... ++ ... +
P388/ADR ... ++ +/++ ++ ++ +
Scores: -, negative; + to +++, low to high positivity.
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Figure 4 Immunocytochemistry for bcl-X in P388 (A) and P388/SPR cells
(B). Cells were counterstained with methyl green; magnification 1000-fold.
Contrary to the absence of bcl-Xin parental cells (A), a striking
overexpression of bcl-X was detected predominantly in large, differentiated
mutant cells (B)
to 23% ofthe level of P388 cells (data not shown). The expression
of bax protein was reduced by approximately 40% in P388/SPR
cells compared with the parental cells. In contrast, a significant
overexpression of bcl-X-L protein by a median factor of 9.7 could
be detected in this subline (Figure 3B). Especially larger, more
differentiated cells of the P388/SPR subline displayed a striking
cytoplasmic overloading with bcl-X (Figure 4B). All semiquantita-
tive results ofimmunocytochemistry are summarized in Table 2. In
addition to the differences in the expression of bcl-2 and related
proteins, the c-myc protein was slightly elevated and the retino-
blastoma gene product reduced in the P388/SPR variant. All cell
lines expressed the mutantp53 protein at similar levels.
To assess cytotoxin-induced apoptosis, a quantitative ELISA
measuring cytoplasmic DNA-histone complexes (nucleosomes)
was used. Apoptotic DNA fragmentation in P388 cells was readily
induced by DOX (Figure 5A) and cisplatin (Figure SB), whereas
nucleosomes in P388/SPR cells were virtually undetectable within
a 6-h period.
Transfection of Bcl-X-L into P388 cells
To confirm the role ofbcl-Xin modulating chemoresistance, human
bcl-X cDNA was transfected into P388 cells. The data are summa-
rized in Table 3. In comparison to the 'mock' transfected P388/Neo
cells, the bcl-X-L overexpressing clone displayed a relatively high
level of cross-resistance to cisplatin and an intermediate level of
resistance to DOX, VP-16 and to 4-OH-cyclophosphamide. Cross-
resistance to vinblastine was marginal. Given the contributory role
of P-gp in the P388/SPR variant, the overall cross-resistance
pattern was similar to that ofthe P388/SPR cells.
DISCUSSION
The spontaneously resistant variant of murine P388 leukaemia is
characterized by an unusual phenotype with cross-resistance to
many non-MDR-related cytotoxins, such as the topoisomerase I
inhibitor camptothecin, alkylators, aphidicolin and UV light.
The major alteration in gene expression, which was found associ-
ated with this phenotype, is the striking overexpression of the
long form of the bcl-X protein. The bcl-X gene encodes two
proteins with opposing effects on apoptosis via an alternative
splicing mechanism (Boise et al, 1993). The larger ofthese, bcl-X-

































Figure 5 Induction of apoptotic DNA fragmentation in P388 (0) and
P388/SPR (0) cells. Nucleosomes generated in the cytoplasmic fraction of 2
X 103 cells after incubation with 1 gM doxorubicin (A) or 10 gM cisplatin (B) at
370C for time periods indicated were quantitatively detected by ELISA.
Illustrated is a representative experiment (n=3) done in duplicate
accelerates cell death rates. Accordingly, bcl-X-L does confer
chemoresistance (Minn et al, 1995), whereas bcl-X-S sensitizes
cells to chemotherapy as has been demonstrated by recent trans-
fection studies (Sumantran et al, 1995).
Both DOX and VP-16 induce apoptosis (Ling et al, 1993; Lowe
et al, 1993). Several oncogenes and tumour-suppressor genes have
been identified that regulate the apoptotic cell death, including bcl-
2 and related proteins, c-myc andp53 (for review see Reed, 1994;
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Table 3 Resistance phenotype of bcl-X-L transfected P388 cells in
comparison with 'mock' transfected cells
P388/Neo P388/Bcl-X-L Resistance
Drugs 1C50(nM) lc5O(nM) factora
Doxorubicin 8.2 (6.9-9.7)b 32 (27-38) 4
VP-16 23 (21-25) 95 (61-129) 4
Vinblastine 0.45 (0.40-0.51) 0.69 (0.62-0.74) 1.5
Cisplatin 130 (94-180) 1341 (995-1686) 10
4-OH-Cyclophosphamide 294 (258-335) 1191(597-1785) 4
Resistance factor: x-fold increase of IC50 in comparison with P388/Neo cells
as determined by MTT assays (n 2 4) after 48-h drug exposure (aall numbers
P<0.05). bNumbers: means (95% confidence limits).
Thompson, 1995). Overexpression of the 26-kDa bcl-2 protein in
transfected cell lines prevents apoptosis and confers resistance to a
number of cytotoxic anti-cancer agents, including topo II
inhibitors (Miyashita and Reed, 1993). bcl-2 forms heterodimers
with the 21-kDa protein bax, which counters the death-repressor
activity of bcl-2 (Oltvai et al, 1993). Moreover, the bcl-2 protein
functionally interacts with c-myc by specifically abrogating c-
myc-induced apoptosis without affecting its mitogenic function
(Fanidi et al, 1992). Similarly, wild-type p53 plays a crucial role
in the execution ofapoptosis after DNA damage induced by radia-
tion and chemotherapeutic drugs (Clarke et al, 1993) and bcl-2
has been shown to block p53-induced cell death (Miyashita et al,
1994). All three P388 sublines expressed mutant p53 at similar
levels by immunocytochemistry. The P388/SPR variant demon-
strated a significantly decreased expression of bcl-2 mRNA, and
bcl-2 protein was not detectable by Western blotting. Although
bax protein expression was also slightly reduced, the ratio of bax
to bcl-2 was still clearly higher than in the parental cells, which by
itself might suggest a tendency to a reduced survival ofP388/SPR
cells according to a proposed model (Oltvai et al, 1993). This
apparent contradiction might be explained by the finding that bel-
X-L, but not bcl-X-S, also heterodimerizes with bax and opposes
bax-induced cell death (Sato et al, 1994). When considered the
dominant role of bcl-X-L, which is in agreement with data from
previous studies of bcl-X-L (Sato et al, 1994; Minn et al, 1995;
Datta et al, 1995), the finding of overexpression of bcl-X-L is
highly likely to contribute to the resistant phenotype ofthese cells.
Moreover, transfection of bcl-X-L into P388 cells resulted in a
similar phenotype with broad cross-resistance.
Several findings suggest a contributory but limited role ofmdrl
for the resistance phenotype of P388/SPR cells: (1) this mutant
displays some cross-resistance to vinca-alkaloids; (2) the addition
ofthe MDR modulator cyclosporine had a minimal effect on DOX
and VP-16 resistance; (3) the degree of impairment in accumula-
tion of vinblastine is modest; and (4) in contrast to the wild-type
P388 cells, mdrl and P-gp expression was detectable in P388/SPR
cells, but very low compared with the classical MDR variant,
P388/ADR.
We could not detect consistent changes of topo II or GSH
metabolism in P388/SPR cells. In the case of topo II, no signifi-
cant reduction of mRNA levels of both isoforms or decreased
formation ofcleavable complexes could be observed in P388/SPR
cells compared with P388 cells. Although topo Ila protein levels
appeared to be decreased in this variant, topo IIlB levels were
increased and have been shown to have significance in conferring
drug resistance (Harker et al, 1991). In addition, decatenation
activity in nuclear extracts from both cell lines was similar (J-S
KOhl, unpublished data).
As suggested by karyotypic analysis, P388/SPR cells emerged
from clonal expansion during repeated in vivo passaging without
prior drug selection (Dr David Streeter, personal communication).
No growth advantage of P388/SPR cells could be observed in
vitro; however, the cells were more resistant to overgrowth and
serum deprivation (J-S Kuhl, unpublished data). Therefore, it
might be speculated that the observed overexpression of the bel-
X-L and c-myc proteins, as well as decreased levels of the
retinoblastoma gene product, conferred some survival advantage
in vivo that presumably permitted this variant to replace the
parental P388 cells. Although the resistance mechanisms involved
in P388/SPR cells may be multifactorial, the striking overexpres-
sion ofbcl-X-L observed in these cells may provide an explanation
for the novel phenotype of this drug-resistant variant. The
P388/SPR cell line serves as an interesting example of sponta-
neously occurring overexpression of bcl-X-L in association with
broad cross-resistance to anti-tumour agents.
ABBREVIATIONS
Bax, bcl-2-associated X protein; bcl-X-L, long form of bcl-X;
DOX, doxorubicin; GSH, glutathione; GST, glutathione-S-trans-
ferase; IC50, drug concentration which reduces specific absorbance
to 50% of control levels; MDR, multidrug resistance; MTT, 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolin bromide; PBS,
phosphate-buffered saline; P-gp, P-glycoprotein; RT-PCR, reverse
transcription-polymerase chain reaction; topo II OtJ3, topoiso-
merase II ax (170-kDa isoform)/P (180-kDa isoform); VP-16,
etoposide.
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